Omnicell (NASDAQ:OMCL – Get Free Report) will likely be releasing its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Omnicell to announce earnings of $0.4175 per share and revenue of $304.43 million for the quarter. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:30 AM ET.
Omnicell (NASDAQ:OMCL – Get Free Report) last released its earnings results on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.47. The firm had revenue of $312.21 million during the quarter, compared to analysts’ expectations of $310.21 million. The business’s revenue was up 7.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.45 EPS. On average, analysts expect Omnicell to post $1.41 EPS for the current fiscal year and $1.03 EPS for the next fiscal year.
Omnicell Stock Down 0.6%
Shares of NASDAQ:OMCL opened at $36.76 on Wednesday. Omnicell has a 1 year low of $29.09 and a 1 year high of $55.00. The business’s 50 day moving average price is $34.57 and its 200-day moving average price is $39.33.
Analyst Upgrades and Downgrades
A number of brokerages have weighed in on OMCL. Weiss Ratings upgraded Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 18th. Zacks Research raised shares of Omnicell from a “strong sell” rating to a “hold” rating in a research note on Monday, September 7th. KeyCorp reaffirmed an “overweight” rating on shares of Omnicell in a report on Monday, August 24th. Wells Fargo & Company dropped their target price on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Finally, Piper Sandler reiterated an “overweight” rating and issued a $45.00 target price (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Omnicell has a consensus rating of “Moderate Buy” and a consensus target price of $57.86.
Get Our Latest Stock Report on Omnicell
About Omnicell
Omnicell, Inc develops medication management and adherence solutions for health care providers, pharmacies and patients. Its technologies are designed to help automate medication dispensing, improve inventory control, support clinical workflows and enhance medication access and adherence across the care continuum.
The company’s product portfolio includes automated dispensing cabinets for hospitals and health systems, central pharmacy and intravenous compounding automation, medication packaging and adherence solutions, and software for analytics, inventory management and pharmacy operations.
Read More
- Five stocks we like better than Omnicell
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.
